PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.32%
Cash & equivalents declining -7.32% while CRVO's grows 16.22%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-7.32%
Below half of CRVO's -16.58%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.49%
Other current assets growth 50-75% of CRVO's -89.10%. Bruce Berkowitz notes fewer expansions. Possibly simpler working capital.
-6.31%
0.5-0.75x CRVO's -11.74%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-8.93%
Both CRVO and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.62%
Less than half of CRVO's -100.00%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-7.75%
Below half of CRVO's -100.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-6.35%
0.5-0.75x CRVO's -11.87%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.18%
50-75% of CRVO's 9.61%. Bruce Berkowitz notes a more controlled liability line.
5.07%
Less than half of CRVO's 19.50%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.44%
Less than half of CRVO's -100.00%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
0.54%
Less than half of CRVO's 19.50%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.80%
Below half CRVO's -10.47%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.26%
Similar yoy to CRVO's -14.10%. Walter Schloss sees parallel net worth trends.
-6.35%
0.5-0.75x CRVO's -11.87%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
-8.07%
Higher Total Debt Growth compared to CRVO's zero value, indicating worse performance.
7.30%
Less than half of CRVO's -16.22%. David Dodd sees better deleveraging or stronger cash buildup than competitor.